Media

Wilson Therapeutics announces that WTX101 meets the primary endpoint in Phase 2 study in Wilson Disease

Nordic Nanovector: Single-dose Betalutin® shows promising efficacy, improved duration of response and favourable safety in relapsed NHL patients

Nordic Nanovector to Present at the Nordic-American Life Sciences Conference in New York

Strongbridge Biopharma plc Announces Promotion of Fredric Cohen, M.D., to Chief Medical Officer

Onxeo Strengthens AsiDNA Patent Protection in Europe

Wilson Therapeutics AB (publ) Interim Report January 1 – September 30, 2016

Nordic Nanovector ASA – Results for third quarter 2016

Altimmune to Present at the 28th Annual Piper Jaffray Healthcare Conference

Favorable outcome from Zubsolv® patent infringement litigation against Actavis